[
    [
        {
            "time": "",
            "original_text": "康华生物：主打产品获批涉及行贿 销售费用逐年增高 其他违规处罚",
            "features": {
                "keywords": [
                    "康华生物",
                    "主打产品",
                    "获批",
                    "行贿",
                    "销售费用",
                    "逐年增高",
                    "违规处罚"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "康华生物：主打产品获批涉及行贿 销售费用逐年增高 其他违规处罚",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]